A Prospective Diagnostic Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint in Primary and Secondary/Tertiary Care
Eli Lilly and Company
Summary
The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.
Description
There are two types of participants in this study, HCP participants and patient participants. Outcome measures relate to the HCP management of patient participants.
Eligibility
- Age range
- 50+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Health Care Provider (HCP) Definitions * Primary care physician (PCPs): physicians such as family medicine practitioners and internists who do not specialize in neurological care. * Secondary care physicians (SCPs): physicians such as geriatricians or neurologists who see patients for specific reasons. * Tertiary care physicians (TCPs): specialty neurologists who focus on certain neurological conditions. HCP Participant Selection Criteria * HCP inclusion criterion for each category of HCP is as follows: * Group 1: PCPs who routinely evaluate and manage patients over…
Interventions
- Diagnostic TestP-tau217
Blood biomarker testing
- OtherStandard of Care
Standard of care
Location
- SiteRx Virtual SiteNew York, New York